The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
The efficacy and superiority in the treatment of primary hypertension with Nifedipine Substained-release Tablets Ⅱ
Author(s): 
Pages: 739-741
Year: Issue:  12
Journal: Qilu Pharmaceutical Affairs

Keyword:  硝苯地平缓释片Ⅱ原发性高血压临床疗效优越性;
Abstract: 目的 评价硝苯地平缓释片Ⅱ(伲福达)治疗原发性高血压的疗效.方法 选取2016年3月~2017年3月期间本院收治的140例原发性高血压患者作为研究对象,随机分为对照组(68例)和观察组(72例).对照组采用美托洛尔治疗,观察组采用硝苯地平缓释片Ⅱ治疗,治疗期间监测两组患者血压和心率变化,并比较两组临床疗效和用药安全性.结果 治疗后,观察组SBP/DBP指标水平(128.56±10.23/84.24±6.02 mmHg)均显著低于对照组(143.58±11.71/90.47±5.24 mmHg),组间有差异(P<0.05).观察组总有效率(94.44%,68/72)显著高于对照组(76.47%,52/68),组间有差异(P<0.05).观察组不良反应发生率(13.89%,10/72)略高于对照组(11.76%,8/68),但无统计学差异(P<0.05).结论 原发性高血压患者应用伲福达治疗效果可靠,可有效提升降压效果,改善患者心率,临床应用安全高效.
Related Articles
No related articles found